Phillip J. Koo, MD

Banner MD Anderson Cancer Center

Phoenix, Arizona

Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.

Disclosures:

Dr. Koo has the following disclosures:
Speaker: Bayer
Consultant: Janssen

Talks by Phillip J. Koo, MD

FDUS 2018 – Next Generation Imaging in Localized Prostate Cancer

Posted by Phillip J. Koo, MD | Sep 2018

Phillip J. Koo, MD, led the “Next Generation Imaging in Localized Prostate Cancer” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.

Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Posted by Phillip J. Koo, MD | Jul 2018

Phillip J. Koo, MD, Chair of the Prostate Cancer Outreach Working Group, discusses advances in nuclear medicine and imaging, basic concepts of the theranostic approach, and controversies in this field. Following Dr. Koo’s discussion of the current state of nuclear medicine, Susan F. Slovin, MD, PhD, discusses the three iterations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR).

Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223

Posted by Phillip J. Koo, MD | Apr 2018

Philip J. Koo, MD, describes the mechanism of action of Radium-223 in prostate cancer treatment, options for combining and layering Radium-223 with other drugs, and how the field of radiation is evolving. He also addresses the controversial ERA 223 trial results.

Imaging of Prostate Cancer Patients Following Definitive Therapy

Posted by Phillip J. Koo, MD | Feb 2018

Dr. Phillip J. Koo, MD, discusses advanced tools such as multi-parametric MRI and PET/CT for prostate cancer imaging, and how they outperform traditional, previously available methods.

Therapeutic Radiopharmaceuticals and the Emergence of Theranostics

Posted by Phillip J. Koo, MD | Jan 2018

Dr. Phillip J. Koo, MD, discusses the use of radiopharmaceuticals in prostate cancer treatment, as well as the area of theranostics. He goes into detail on the process of choosing these radiopharmaceuticals and trying to determine the best ones to use in various situations in regards to prostate cancer.